Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces US FDA Approval of VAXNEUVANCE™ for Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes

Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes

AbbVie

American Express

Bank of New York Mellon

Bristol-Myers

Chevron

Globe Life Inc

Kraft Heinz

Coca-Cola

Mastercard

Sirius XM Holdings Inc

STORE Capital

U.S. Bancorp

Verizon

This Buffett holdings list from Kiplinger first appeared 5/17/21 on line. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 7/13/21 YCharts data. 8 of 46 current Berkshire Hathaway owned stocks pay dividends. As of 7/13/21 the top ten ranged 2.72%-5.16% by annual yield and ranged 19.87%-67.17% per broker estimated price target upsides.

Buffett 46 July Holdings Include 28 Dividend Payers

Merck & Co Inc (NYSE: MRK) has announced positive event-free survival (EFS) data from the pivotal neoadjuvant/adjuvant Phase 3 study KEYNOTE-522 trial of Keytruda (pembrolizumab) in breast cancer.  The trial investigated neoadjuvant (delivered before the primary treatment) Keytruda, plus chemo followed by adjuvant Keytruda as monotherapy (Keytruda regime) compared with neoadjuvant chemotherapy followed by adjuvant placebo in patients with high-risk early-stage triple-negative breast cancer (TNBC).

Merck Touts Encouraging Event-Free Survival For Keytruda Regime Over Placebo-Chemo Regime In Breast Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemo Before Surgery and Cont'd as Single Agent Showed Stat Sig Event-Free Survival vs Neoadjuvant Chemo in High-Risk Early-Stage TNBC

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC

Goldman Sachs

IDEXX Laboratories

Among the 32 stocks Goldman Sachs Group Inc. ( GS , Financial) finds attractive, six are in health care, including the highly diversified Mettler-Toledo International Inc. ( MTD , Financial), a name that might not be familiar to industry followers.

Goldman Sachs Names Merck, Mettler and IDEXX Attractive Health Care Stocks

Merck & Co Inc (NYSE: MRK) and its collaborating partner Ridgeback Biotherapeutics announced the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials of molnupiravir in non-hospitalized COVID-19 patients. The data were presented at the European Congress of Clinical Microbiology & Infectious Diseases.

Merck, Ridgeback Highlight Interim Molnupiravir Data In Non-Hospitalized COVID-19 Patients

Avnet

Cummins

Eastman Chemical

Eversource Energy

FlexShares STOXX US ESG Impact Index Fund

General Mills

Hanesbrands

Kimberly-Clark

Principal Financial Group

Prudential Financial

Regions Financial

February 15, 2021, Barron's-Weekly published their fourth-ever 100 Most Sustainable Companies as-determined-by Calvert Research and Management division of Eaton Vance. These are "Barron's Sustainable 100," or BS100. The top-ten BS100 showed net gains ranging 17.34%-29.5% from PFG, RL, AVT, HPQ, MRK, CMI, RF, EMN, HBI, and KO. Technology, Consumer Cyclical, and Industrial sectors led; Energy was not represented.

Barron's 100 Top ESG Equities Show 77 With Dividends And 2 With Ideal Returns

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021

Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Interim Results from Phase 2/3 Studies of Molnupiravir, Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at ECCMID

Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

bluebird bio

Organon & Co

Neither healthcare stock has performed well so far this year.

Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?

Merck is a great pharma play with its coronavirus pill and strong, consistent dividend payouts. MRK stock is a solid buy.

The Coronavirus Pill Makes Merck a Solid Buy

AT&T

Investors shouldn't get too comfortable with these yields.

Danger Lurks for These 2 High-Yield Dividend Stocks

Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.

Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer

"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration." 30 Dow stocks represent nine of eleven sectors. Dow tracks utilities as a separate index and omits real estate. Broker top ten target-estimated net-gains ranged 11.1%-22.4% topped by MRK 7/2/21.

July Dogs Of The Dow: Merck Is Top Net Gainer; Chevron Is Top Yielder

OncoSec Medical Inc (NASDAQ: ONCS) will evaluate its DNA-plasmid interleukin-12 (IL-12) TAVO (tavokinogene telseplasmid) with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in KEYNOTE-C87 Phase 3 trial.  The planned trial will evaluate the overall survival of patients treated with the TAVO / Keytruda combination versus standard of care in late-stage patients with metastatic melanoma who are refractory to immune checkpoint therapy.

OncoSec Stock Jumps On Anti-Cancer Gene Therapy Trial Collaboration With Merck In Melanoma

Clorox

Cabot Oil & Gas

Quest Diagnostics

Gilead Sciences

Hologic

Labcorp Holdings Inc

Pfizer

PerkinElmer

Regeneron Pharmaceuticals

Texas Instruments

The shares of these S&P 500 companies are not only priced right—they also could hold up better during volatility.

11 Quality Stocks That Are Relatively Cheap

KENILWORTH, N.J.--(BUSINESS WIRE)---- $mrk #merck--FDA Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)

FDA Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)

Shares of Merck & Co. Inc. were up 0.7% in trading on Friday, the day after the company said it will voluntarily withdraw an accelerated approval for Keytruda as a third-line treatment for some patients with gastric cancer in the next six months. Keytruda is Merck's top-selling drug; it brought in $14.4 billion in sales in 2020.

Mizuho: Merck withdrawing Keytruda as a gastric cancer treatment won't impact the stock

Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.

Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda

Amgen

Broadcom

CMS Energy

Cisco Systems

Evergy Inc

Kellogg

Lockheed Martin

Alliant Energy

M&T Bank

PepsiCo

Philip Morris

Southern Company

Sempra Energy

Truist Financial

Vanguard High Dividend Yield ETF

WEC Energy Group

Xcel Energy

There are 20 High-Yield Dividend Stocks on the July 2021 watchlist. The watchlist lost 1.73% in June but is still up over 35% since November 2020.

High Yield Dividend Stocks For July 2021

News for Merck Stock (MRK)